RENAU.UNSP.ARD 1/5 EO-20
Research RENAU.UNSP.ARD 1/5 EO-20 (56S0) on Bullrun: market cap EUR 17.22B, P/E 59.0, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker56S0
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyEUR
- Market capEUR 17.22B
- P/E59.0
- Dividend yield0.4%
- Financial periodQ2 2026
- RevenueEUR 765.70M
- Net incomeEUR 93.00M
- Free cash flowEUR 75.10M
- Gross margin46.9%
Valuation Snapshot
latest market cap is EUR 17.22B; P/E is 59.0; dividend yield is 0.4%.
Peer valuation comparison
Latest P/E is 59x versus a Healthcare sector median of 24.46x (141.2% above).
Latest dividend yield is 0.36% versus a Healthcare sector median of 2.11% (82.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 17.22B | 59.0 | 0.4% | 0.07 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.07 EUR, yield 0.4%.
About RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is RENAU.UNSP.ARD 1/5 EO-20's market cap?
RENAU.UNSP.ARD 1/5 EO-20's market capitalization is EUR 17.22B.
What is RENAU.UNSP.ARD 1/5 EO-20's P/E ratio?
RENAU.UNSP.ARD 1/5 EO-20's price-to-earnings (P/E) ratio is 59.0.
Does RENAU.UNSP.ARD 1/5 EO-20 pay a dividend?
RENAU.UNSP.ARD 1/5 EO-20 has a dividend yield of 0.4%.
What does RENAU.UNSP.ARD 1/5 EO-20 do?
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.